**Name of Journal: *World Journal of Clinical Oncology***

**ESPS Manuscript NO: 29772**

**Manuscript Type: Original Article**

***Basic Study***

**Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer**

Harmon T *et al.* Nanoparticle-linked antagonist for leptin signaling inhibition in BC

**Tia Harmon, Adriana Harbuzariu, Viola Lanier, Crystal C Lipsey, Ward Kirlin, Lily Yang, Ruben R Gonzalez-Perez**

**Tia Harmon, Adriana Harbuzariu, Viola Lanier, Crystal C Lipsey, Ward Kirlin, Ruben R Gonzalez-Perez,** Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, United States

**Lily Yang,** Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, United States

**Author contributions:** All authors contributed to this manuscript; Harmon T, Gonzalez-Perez RR and Yang L contributed to the study concept and design; Harbuzariu A, Lanier V, Lipsey CC and Kirlin W contributed to data accumulation, analysis and interpretation.

**Supported by** The National Cancer Institute at the National Institutes of Health (1R41 CA183399-01A1 to Ruben R Gonzalez-Perez; 5U54 CA118638, S21 MD000101, 5G12 MD0076021, G12 RR026250-03, NIH RR03034 and 1C06 RR18386 to Morehouse School of Medicine); the National Institute of General Medical Sciences, Research Initiative for Scientific Enhancement Program (RISE 5R25 GM058268 to Tia Harmon); and the Congressionally Directed Medical Research Programs-Department of Defense (CDMRP DOD W81XWH-13-1-0382 to Ruben R Gonzalez-Perez).

**Informed consent statement:** N/A.

**Institutional animal care and use committee statement:** N/A.

**Conflict-of-interest statement:** The authors of this manuscript indicate that there are no known conflicts of interest.

**Data sharing statement:** None.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Ruben R Gonzalez-Perez, PhD,** Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, 720 Westview Drive, Hugh Gloster Suite 329, Atlanta, GA 30310, United States. rgonzalez@msm.edu

**Telephone:** +1-404-7521581

**Received:** August 27, 2016

**Peer-review started:** August 29, 2016

**First decision:** November 14, 2016

**Revised:** December 6, 2016

**Accepted:** December 27, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To develop a leptin peptide receptor antagonist linked to nanoparticles and determine its effect on viability of breast cancer cells.

***METHODS***

The leptin antagonist,LPrA2, was coupled *via* EDAC [1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide] to iron oxide nanoparticles (IONP-LPrA2) to increase its efficacy. IONP-LPrA2 conjugation was confirmed by Western blot and nanoparticle tracking analysis. Human triple negative breast cancer (TNBC) MDA-MB-231, HCC1806 and estrogen receptor positive (ER+) MCF-7 cells were analyzed for the expression of the leptin receptor, Ob-R. The effects of leptin and antagonist on levels of leptin-induced STAT3 phosphorylation and cyclin D1, cell cycle progression, cell proliferation, and tumorsphere formation in breast cancer cells were determined. Doses of the chemotherapeutics [Cisplatin (Cis), Cyclophosphamide (CTX), Doxorubicin (Dox) and Paclitaxel (PTX)] to effectively reduce cell viability were calculated. The effects of combination treatments of IONP-LPrA2 and chemotherapeutics on cell viability were determined.

***RESULTS***

Western blot analysis of coupling reaction products identified IONP-LPrA2 at approximately 100 kD. IONP-LPrA2 significantly decreased leptin-induced pSTAT3 levels in HCC1806 cells and drastically decreased cyclin D1 levels in all cell lines. IONP-LPrA2 significantly reduced leptin-induced S phase progression and cell proliferation in all breast cancer cell lines and the formation of tumorspheres in MDA-MB-231 cells. Also, IONP-LPrA2 showed an additive effect on the reduction of breast cancer cell survival with chemotherapeutics. Cis plus IONP-LPrA2 produced a significant reduction in the survival of MDA-MB-231 and HCC1806 cells. CTX plus IONP-LPrA2 caused a significant decrease in the survival of MDA-MB-231 cells. Dox plus IONP-LPrA2 caused a marked reduction in the survival of HCC1806 cells. Although, PTX plus IONP-LPrA2 did not have a major effect on the viability of the breast cancer cells when compared to PTX alone.

***CONCLUSION***

Present data indicate that IONP-LPrA2 may be a useful adjuvant for chemotherapeutic treatment of breast cancer, particularly for TNBC which lacks targeted therapeutic options.

**Key words:** Triple negative breast cancer; Obesity; Leptin; Leptin peptide receptor antagonist 2; Iron oxide nanoparticles; Chemotherapy adjuvant

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Breast cancer is the second leading cause of cancer deaths in women. Triple negative breast cancer is an aggressive subtype that lacks targeted therapy. Obesity is a risk factor for breast cancer and is associated with high leptin levels. Leptin induces the expression of cell cycle associated proteins advancing cell cycle progression. Leptin also increases breast cancer stem cell growth, which promotes chemotherapeutic resistance. We have developed a leptin antagonist linked to iron oxide nanoparticles (IONP-LPrA2) which significantly inhibits leptin-induced cell proliferation and survival of breast cancer cells treated with chemotherapeutics. IONP-LPrA2 can increase chemotherapeutic efficacy in breast cancer.

Harmon T, Harbuzariu A, Lanier V, Lipsey CC, Kirlin W, Yang L, Gonzalez-Perez RR. Nanoparticle-linked antagonist for leptin signaling inhibition in breast cancer. *World J Clin Oncol* 2016; In press

**INTRODUCTION**

The American Cancer Society estimates that there will be nearly 300000 new breast cancer cases diagnosed worldwide and approximately 50000 women will die from breast cancer in 2016[1]. Triple negative breast cancer (TNBC) accounts for 15% of all breast cancer diagnoses. TNBC is a subtype of breast cancer characterized by the lack of expression of the estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor-2 (HER2)[1,2]. Due to the absence of receptor expression; this form of breast cancer, which predominantly affects younger, African American and Hispanic patients lacks targeted therapeutic options[3]. TNBC patients are commonly treated with chemotherapy; however these patients make up approximately 30% of breast cancer-related deaths annually[4]. This necessitates the development of targeted therapies for this more aggressive form of the disease.

There are many factors that increase the risk of developing TNBC including environment, genetic susceptibility, and obesity[5]. Obesity has a negative impact on breast cancer patient survival and, like TNBC, is associated with an increased risk of recurrence[6]. Obesity is correlated to high levels of leptin, a cytokine produced by adipose tissue which regulates satiety. The leptin signaling pathway occurs in approximately 80% of breast cancers[7]. The binding of leptin to its receptor, Ob-R, leads to activation of pathways involved in cell proliferation, migration, and survival[8]. Leptin is a survival factor in breast cancer and may have the ability to limit the effectiveness of chemotherapy drugs by activating the JAK2/STAT3, MAPK/ERK, and PI3/Akt signaling pathways[9,10] Therefore leptin signaling inhibition has become a promising therapeutic area for breast cancer, particularly in the case of TNBC for which there is no targeted therapy[11].

The binding of leptin to Ob-R upregulates Notch, interleukin 1 (IL-1), vascular endothelial growth factor (VEGF), and its receptor VEGFR2; which promote breast cancer cell survival and angiogenesis[12]. The harmful effects of leptin signaling on breast cancer onset and progression have been shown to be diminished by the leptin peptide receptor antagonist 2 (LPrA2)[13]. LPrA2 and the pegylated form (PEG-LPrA2) have been shown to cause a delay in cancer onset and progression as well as a reduction in 4T1-tumor growth in BALB/C mice[14]. Additionally, PEG-LPrA2 has been shown to decrease MDA-MB-231 and MCF-7-tumor growth in SCID mice[15]. In another study, diet-induced obese (DIO) C57BL/6J mice treated with the carcinogen 7, 12-Dimethylbenz (a) anthracene (DMBA) along with PEG-LPrA2 did not develop tumors[16]. Evidence of the anti-tumor activity of LPrA2 provides mounting evidence for its usefulness in cancer therapy.

The leptin signaling pathway plays a major role in breast cancer cell growth, angiogenesis, as well as metastasis and invasion[8]. Although the leptin antagonist LPrA2 attenuates leptin signaling, it is limited by its insolubility in water and short half-life of 1-2 h**[**14**,**17,18]. Here we describe the coupling of LPrA2 to a nanoparticle delivery system which uses iron oxide nanoparticles (IONPs) to capture multiple LPrA2 peptides. We assessed the conjugation of LPrA2 to IONPs (IONP-LPrA2) to determine the inhibitory effect on breast cancer cell growth and survival. Because LPrA2 decreases breast cancer tumor growth and chemotherapy is widely used in the treatment of breast cancer, we sought to assess if combining IONP-LPrA2 and chemotherapeutic drugs would allow for reduction of the effective dose. Thus, we evaluated the survival of human breast cancer cell lines with IONP-LPrA2 and a panel of anti-cancer drugs.

**MATERIALS AND METHODS**

***Reagents and antibodies***

IONPs were obtained from Ocean Nanotech San Diego, CA. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC), Sulfo-NHS, and other chemicals were purchased from Sigma Aldrich St. Louis, MO.Ob-R (sc-8325), Cyclin D1 (sc-246), pSTAT3 (sc-8059), STAT3 (sc-8019) antibodies were purchased from Santa Cruz Biotechnology Santa Cruz, CA. Anti-rabbit and anti-mouse conjugated to horseradish peroxidase were obtained from Bio-Rad Laboratories Hercules, CA. Dulbecco’s Modified Eagles Medium (DMEM), Iscove’s Modified Dulbecco’s Medium (IMEM), Protease and Phosphatase Inhibitor cocktails, Penicillin/Streptomycin, Slide-a-lyzer dialysis cassette, and Western blotting chemiluminescence substrate were purchased from Thermo Fisher Scientific Rockford, IL. Mammocult complete medium was obtained from Stem Cell Technologies Vancouver, BC. Fetal bovine serum was obtained from Med Supply Partners Atlanta, GA. Leptin was purchased from R and D Systems Minneapolis, MN. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) kit was purchased from Molecular Probes Eugene, OR. Annexin V and Propidium Iodide were obtained from Nexcelom Bioscience Boston, MA. Cisplatin (Cis) was purchased from Millipore Billerica, MA. Cyclophosphamide (CTX), Paclitaxel (PTX), and Doxorubicin (Dox) were obtained from SelleckChem Houston, TX.

***Nanoparticle conjugation***

LPrA2 was synthesized as described[8,19]. LPrA2 was de-salted using the slide-a-lyzer dialysis cassette (Thermo Fisher). LPrA2 was conjugated to IONPs (Ocean Nanotech) by the outlined method[20].

***Western blot analysis***

IONP-LPrA2 was separated by SDS-PAGE. LPrA2 and LPrA2-Scramble (Sc) were used as positive and negative controls, respectively. The proteins were transferred onto nitrocellulose membranes (Bio-Rad). The membranes were probed with an LPrA2 antibody, purified from antigen injected rabbit bleeds. Anti-rabbit IgG conjugated to horseradish peroxidase (Bio-Rad) was used for further protein detection. Chemiluminescent detection of protein expression was displayed by Western blotting substrate (Thermo Fisher).

***Nanoparticle tracking analysis***

Ten k dilutions of the bound and unbound particles were sonicated for 30 min. The size and distribution of the conjugated and unconjugated IONPs were determined by the NanoSight (Malvern Instruments Ltd., Worcestershire, United Kingdom).

***Cell culture***

Human ER+ MCF-7 cells in addition to TNBC MDA-MB-231 and HCC1806 cells (American Type Culture Collection, ATCC, Manassas, VA) were cultured in DMEM (Thermo Fisher) with 10% FBS and 1% penicillin/streptomycin (Thermo Fisher) and maintained in an incubator at 37 °C with 5% CO2.

***Cell lysis and immunoblotting analysis***

Cells were seeded at 2 × 105 in 6 well cell culture plates and grown to 70%-80% confluence. The cells were treated with leptin (1.2 nmol/L) (R and D Systems), or IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L) for 24-48 h. Basal cells served as untreated controls. The cells were lysed with RIPA buffer (Sigma) containing protease/phosphatase inhibitors (Thermo Fisher). Immunoblotting analysis was performed as described[21]. The membranes were incubated with Ob-R, cyclin D1, pSTAT3, and STAT3 (Santa Cruz Biotechnology) antibodies overnight at 4 °C. GAPDH (Sigma) was used as a protein loading control. Relative protein levels were determined by Image J software (National Institute of Health, NIH).

***Cell cycle analysis***

Cells were seeded at 2 × 105 in 6 well cell culture plates and grown to 70%-80% confluence. They were treated with IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L) at indicated concentrations for 24-48 h. Leptin and unconjugated LPrA2 served as controls. The cells were trypsinized, washed with 1 × PBS, and resuspended in cold 100% methanol (Sigma). They ­were stored at -20 °C prior to analysis (< 1 wk). Afterward, the cells were centrifuged to remove the methanol. They were resuspended in 50 µL propidium iodide (PI) (Nexcelom) and incubated at 37 °C for 40 min. The cells were centrifuged to remove the PI, resuspended in 1 × PBS, and analyzed by the Nexcelom Cellometer Vision® image based cytometer to determine the percentage of cells in the S phase of the cell cycle.

***MTT assay***

Cells were seeded at 5 × 103 in 96 well cell culture plates and grown to 70%-80% confluence. The cells were treated with leptin (1.2 nmol/L), or IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L) for 24-48 h. Basal cells served as untreated controls. The media was removed from the cells, the wells were washed with 1 × PBS, and 200μl of IMEM (Thermo Fisher) together with 10 μL of sterile 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 5 mg/mL in PBS, (Molecular Probes) were added. The plates were incubated for 4 h at 37 °C. Following incubation the media was removed, 50 μL of Dimethyl sulfoxide (DMSO) was added to the wells, and the plates were incubated at 37 °C for 30 min. The absorbance was read at 540 nm using a microplate reader (Molecular Devices) to measure cell proliferation.

***Tumorsphere formation***

MDA-MB-231 cells were seeded at 5 × 103-2 × 104 cells/mL in low attachment plates and grown for 1-2 wk in Mammocult complete medium (Stem Cell Technologies) supplemented with heparin and hydrocortisone. The resulting tumorspheres were treated with leptin (1.2 nmol/L), or IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L). Basal colonies served as untreated controls. The tumorspheres were visually assessed by light microscopy. The size of the tumorspheres were determined and colonies were counted manually in triplicate.

***Apoptosis assay***

Cells were seeded at 2 × 105 in 6 well cell culture plates and grown to 70%-80% confluence. They were treated with the chemotherapeutic drugs: Cis (Millipore), CTX, PTX, and Dox (SelleckChem) in 5% FBS with or without IONP-LPrA2 for time periods ranging from 1-6 d. Before trypsinizing, the supernatants were transferred into microfuge tubes for subsequent analysis. The trypsinized cells were added to the supernatants and centrifuged. The pellets were washed with 1 × PBS and resuspended in Annexin V binding buffer (Nexcelom). Annexin V/FITC, and PI, 5 µL each (Nexcelom) were added with mixing. The samples were incubated in the dark at room temperature for 15 min. The cells were washed with 1 × PBS, centrifuged, and resuspended in Annexin V binding buffer to a concentration of 30000 cells per 20 µL. The samples were analyzed by the Cellometer Vision. The viability was determined by multiplying the percentage of live cells by the total cell count.

***Statistical analysis***

All experiments were performed in triplicate. One-way ANOVA (SigmaPlot) was used to determine statistical significance among treatment groups and controls. Data presented as the average ± standard deviation (SD). *P* values of *P* < 0.05 were considered statistically significant.

***Biostatistics statement***

The statistical review was performed by Ward Kirlin, PhD. The appropriate ANOVA of variance was performed on the data presented in this paper, and levels of statistical significance are based on the F-values and Tukey’s multiple comparisons between group means as determined using SigmaPlot (Systat Software, Inc.). Mean + SDs are indicated in the graphical analysis, based on replicates of densitometry analysis of Western blots, the percentage of cells in S-phase of the cell cycle, or percentage of proliferating cells as indicated in the figures.

**RESULTS**

***Generation and characterization of IONP-LPrA2***

The leptin antagonist, LPrA2, has been shown to inhibit breast cancer growth and progression *in vitro* as well as *in vivo*[2,22,23]. To increase its efficacy, LPrA2 was conjugated to IONPs. IONPs are amphiphilic and have a 10 nm core[20]. The binding of LPrA2 to IONPs was facilitated by EDAC, which activates the carboxyl group on the IONP surface and allows the formation of an amide bond with the amino group of LPrA2(Figure 1A). To confirm the binding of the LPrA2 peptides to the nanoparticles, the conjugates were analyzed by SDS-PAGE and Western blot. With LPrA2 antibody incubation bands were detected at approximately 100 kD, indicating conjugated LPrA2, and approximately 3 kD indicating unbound LPrA2. Unconjugated LPrA2 and LPrA2-Sc were used as positive and negative controls, respectively (Figure 1B). To further characterize IONP-LPrA2, 10 k dilutions of the conjugated and unconjugated IONPs were measured by NanoSight nanoparticle tracking analysis (Malvern); in which the left and right Y-axes show particle number and percent distribution, and the X-axis displays particle size. The size of the unconjugated IONP was found to be 14 nm while conjugated IONP-LPrA2 measured 20 nm. This data suggests that the conjugation of LPrA2 to IONPs was successful.

***Ob-R expression and effect of IONP-LPrA2 on leptin-induced pSTAT3 and cyclin D1 levels in human breast cancer cells***

In order to determine the effects of IONP-LPrA2 on leptin signaling inhibition, we first had to confirm expression of the leptin receptor, Ob-R, in the human breast cancer cell lines. Immunoprecipitation and subsequent Western blot analysis showed Ob-R expression in MDA-MB-231, HCC1806, and MCF-7 cells (Figure 2A). Leptin signaling activates the JAK2/STAT3, MAPK/ERK, and PI3/Akt signaling pathways, which are implicated in its anti-apoptotic activity[9]. For this reason, we aimed to determine the effect of IONP-LPrA2 treatment on active/phosphorylated, pSTAT3. Leptin significantly increased the level of pSTAT3 in MDA-MB-231 and HCC1806 cells. IONP-LPrA2 significantly inhibited the effect of leptin on pSTAT3 levels in HCC1806 cells. No significant changes occurred in pSTAT3 levels in MCF-7 cells treated with leptin and IONP-LPrA2 (Figure 2B and C). Because leptin has been shown to increase Cdk2 and cyclin D1 levels in MCF-7 cells[14], we sought to determine the effect of IONP-LPrA2 treatment on cyclin D1 expression in MDA-MB-231, HCC1806, and MCF-7 breast cancer cells. Leptin significantly induced cyclin D1 expression in all cell lines (Figure 2B and C). The addition of IONP-LPrA2 significantly inhibited the effect of leptin on cyclin D1 expression in all cell lines (Figures 2B and C). These results suggest that IONP-LPrA2 abrogates the effect of leptin on leptin-induced signaling pathways.

***IONP-LPrA2 inhibits leptin-induced cell cycle progression of human breast cancer cell lines***

Leptin has been shown to increase the expression of cell cycle associated proteins, Cdk2 and cyclin D1[14]. To illustrate the effect of leptin on cell cycle progression, the number of cells in the S phase was determined by cell cycle analysis with the Cellometer Vision (Nexcelom). MDA-MB-231, HCC1806, and MCF-7 human breast cancer cell lines were treated with leptin (1.2 nmol/L) and IONP-LPrA2 plus leptin in order to determine its antagonistic effect. The cells were treated with IONP-LPrA2 concentrations ranging from 0.0018-0.036 pmol/L. MDA-MB-231 and HCC1806 TNBC cell lines were treated for 24 h while the ER+ MCF-7 cells were treated for 48 h to produce an effect. Treatment with leptin caused a significant increase in cell cycle progression in HCC1806 (Figure 3B) and MCF-7 (Figure 3C), but had no significant effect on MDA-MB-231 cells (Figure 3A). Treatment with IONP-LPrA2 plus leptin abrogated leptin-induced cell cycle progression at 0.0018-0.0036 pmol/L in MDA-MB-231, at 0.0018-0.036 pmol/L in HCC1806, and at 0.0018-0.0072 in MCF-7 cells (Figure 3A-C). This data elucidated the effective dilution of IONP-LPrA2 for abrogation of leptin-induced cell cycle progression in each of the cell lines.

***IONP-LPrA2 inhibits leptin-induced cell proliferation in human breast cancer cells***

Leptin signaling stimulates breast cancer cell survival and proliferation[8]. To ascertain the manner in which IONP-LPrA2 affects cell proliferation, an MTT assay was performed. MDA-MB-231, HCC1806, and MCF-7 cell were treated with leptin (1.2 nmol/L) and IONP-LPrA2 (0.0036) plus leptin (1.2 nmol/L). Leptin treatment significantly increased cell proliferation and IONP-LPrA2 significantly diminished the effect of leptin in all of the cell lines (Figure 4). This data indicates that IONP-LPrA2 prevents leptin induction of cell proliferation.

***IONP-LPrA2 decreases MDA-MB-231 tumorsphere formation***

Self-renewal is a hallmark of cancer. Leptin has been shown to increase self-renewal and breast cancer stem cell (BCSC) growth[24]. To learn how IONP-LPrA2 affects BCSC growth, tumorsphere formation was assessed. MDA-MB-231 TNBC cells were treated with leptin (1.2 nmol/L) and IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L). Untreated, basal, MDA-MB-231 cells developed few small and medium colonies (100-200 µm), cells treated with leptin showed a significant increase in the development of medium (200 µm) and large tumorspheres (> 200 µm) in comparison to basal. Cells treated with IONP-LPrA2 plus leptin displayed a significant decrease in medium tumorsphere growth relative to the leptin treated (Figure 5). This data shows that IONP-LPrA2 treatment may decrease BCSC growth.

***The effect of chemotherapeutics on survival of breast cancer cell lines***

Chemotherapy is among the most common treatments for breast cancer in addition to radiation and surgery[25]. To determine the effective dose of chemotherapeutics, cells were treated with a panel of anti-cancer drugs and viability was tested by the Annexin V FITC/PI Assay (Nexcelom). MDA-MB-231, HCC1806, and MCF-7 cells were treated with Cis (0.001-1.1 µmol/L), CTX (0.01-100 µmol/L), Dox (0.01-50 µmol/L), and PTX (0.05-1.0 µmol/L) for time periods ranging from 1-6 d to determine an effective dose to reduce cell viability (Figure 6). Cis and Dox reduced cell viability in 24 h while CTX and PTX treated cells required up to 6 d to produce an effect. All cell lines displayed a similar response to Cis and PTX (Figure 6A and D). MDA-MB-231 cells appeared to be more sensitive to CTX and Dox (Figure 6B and C).

***Determination of the effect of IONP-LPrA2 on survival of breast cancer cells treated with chemotherapeutics***

Chemotherapy has many detrimental side effects; because of this it is advantageous to utilize adjuvant therapies in order to reduce the effective dose. To determine the adjuvant potential of IONP-LPrA2, cells were treated with chemotherapeutics combined with IONP-LPrA2 and analyzed for viability by the Annexin V FITC/PI Assay (Nexcelom). MDA-MB-231, HCC1806, and MCF-7 cells were treated with chemotherapeutics at concentrations determined in Figure 6 in media containing 5% FBS to mimic physiological leptin levels, in addition to IONP-LPrA2 (0.0036 pmol/L) for time periods ranging from 1-6 d. The treatment concentrations were MDA-MB-231 (Cis 0.001 µmol/L, CTX 0.5 µmol/L, Dox 0.4 µmol/L, PTX 0.5 µmol/L); HCC1806 (Cis 0.036 µmol/L, CTX 1 µmol/L, Dox 10 µmol/L, PTX 0.5 µmol/L); and MCF-7 (Cis 0.036 µmol/L, CTX 5 µmol/L, Dox 0.01 µmol/L, PTX 1 µmol/L). MDA-MB-231 TNBC cells treated with IONP-LPrA2 displayed a significant decrease in viable cells when dosed with Cis and CTX (Figure 7A and B). HCC1806 TNBC cells treated with IONP-LPrA2 showed a significant reduction in viable cells when dosed with Cis and Dox (Figure 7A and C). MCF-7 ER+ cells treated with IONP-LPrA2 did not show a significant decrease in viable cells when treated with chemotherapeutics (Figure 7). Although cells were treated with PTX for up to 6 d to reduce cell viability, IONP-LPrA2 showed no additional decrease in viability when combined with PTX (Figure 7D). PTX is an anti-microtubule agent which acts on the M phase of the cell cycle while the other chemotherapeutics act on DNA which affects the S phase[2]. This data suggests that IONP-LPrA2 increases the potency of chemotherapeutics on TNBC cells, particularly anti-cancer drugs which target DNA.

**DISCUSSION**

In spite of methods for early detection of breast cancer, it remains the second leading cause of cancer deaths in women in the United States[1]. TNBC is a subtype of breast cancer characterized by the lack of hormone receptor expression. The absence of hormone receptors makes this more aggressive form of breast cancer even more difficult to treat. Obesity is often associated with poorer outcomes in individuals with breast cancer, particularly those with TNBC. Obesity is characterized by an excess of the inflammatory cytokine, leptin. Elevated leptin levels display a significant correlation with metastasis and lower breast cancer patient survival[26]. The leptin antagonist, LPrA2 has been shown to inhibit leptin signaling in breast and other cancer types, but the actions of LPrA2 are restricted by its low MW of < 3 kD, short half-life, and insolubility in water[8,27]. IONP-LPrA2 was developed to circumvent these limitations. IONPs conjugated to other peptides, such as the amino terminal fragment of urokinase type plasminogen activator (ATF-uPA) are stable for more than 48 h in *in vivo* imaging experiments[20]. IONPs are amphiphilic, small (10 nm core size), and uniformly sized to facilitate delivery which prevents phagocytosis[28]. The characteristics of IONPs make them an ideal delivery system for LPrA2 to target and treat breast cancer. In the present study, IONP-LPrA2 was used to evaluate its ability to inhibit leptin signaling in human breast cancer cells. The data indicates that IONP-LPrA2 abrogates cell cycle progression and acts as an adjuvant when administered with chemotherapeutics.

Decreased levels of pSTAT3 and cyclin D1 with IONP-LPrA2 treatment were shown by Western Blot. Cyclin D1 is a cell cycle regulatory gene. STAT3 is a transcription factor responsible for the regulation of cyclin D1[10]. Decreased levels of pSTAT3 with IONP-LPrA2 treatment were seen at time points as early as 5-15 min post treatment. Previous studies have shown that leptin is mitogenic and increases cyclin D1 in ER+ MCF-7 breast cancer cells[14]. Because leptin increases cyclin D1 and IONP-LPrA2 inhibits the effect of leptin, utilizing agents that target cyclin D1 may be a plausible method to treat breast cancer. In this study, we have shown that IONP-LPrA2 decreases pSTAT3 and cyclin D1. The decreased levels of these leptin-induced targets may inhibit cell cycle progression in ER+ MCF-7 cells as well as MDA-MB-231 and HCC1806 TNBC cells.

Inhibition of cell cycle progression by IONP-LPrA2 was displayed by image based cytometry. Leptin has been shown to increase levels of cyclin D1 and Cdk2[14]. In this study, we show that IONP-LPrA2 decreases cyclin D1 expression, but the effect on cell cycle progression was yet to be determined. Here we show that IONP-LPrA2 treatment decreases the percentage of cells in the S phase of the cell cycle, where DNA is synthesized, as or more effectively than LPrA2 alone. Interestingly, the greatest decrease in the percentage of cells in S phase with IONP-LPrA2 treatment was seen in HCC1806 TNBC cells derived from a non-metastatic squamous cell carcinoma in contrast to MCF-7 and MDA-MB-231 cells derived from metastatic adenocarcinomas. This data suggests that IONP-LPrA2 inhibition of cell cycle progression may reduce the advancement of breast cancer, and may be particularly beneficial in the treatment of non-metastatic and squamous cell carcinomas.

Chemotherapy is the first line of treatment for TNBC. Although TNBC is generally more responsive to chemotherapy than other forms of breast cancer, there is an increased risk of developing drug resistance[29]. BCSC growth and self-renewal play an important role in breast cancer drug resistance and leptin increases the risk[24]. These cells express molecular markers for breast cancer, CD44+CD24-/ALDH+[10]. We have demonstrated that leptin induces *in vitro* BCSC, tumorsphere, formation and treatment with IONP-LPrA2 attenuates the effect of leptin in MDA-MB-231 TNBC cells. These results indicate that IONP-LPrA2 prevents BCSC formation and may decrease chemoresistance in TNBC.

Chemotherapeutic treatment of breast cancer is plagued with high toxicity. Toxic side effects and the development of drug resistance are cause for the development of adjuvant therapies. The need for adjuvant therapies is exacerbated in TNBC patients who often experience relapse and develop resistance to chemotherapy[29]. TNBC is commonly treated with combination chemotherapy[25]. Here, we treated breast cancer cells with a panel of commonly used chemotherapeutics (Cis, CTX, Dox and PTX) in addition to IONP-LPrA2 to test its ability to decrease cell viability more than the drugs alone. We demonstrated that TNBC cells, MDA-MB-231 displayed a significant decrease in viability with Cis and CTX plus IONP-LPrA2; and HCC1806 showed a significant reduction in live cells when treated with Cis and Dox plus IONP-LPrA2. ER+ MCF-7 cells treated with chemotherapeutics plus IONP-LPrA2 did not show a significant decrease in viable cells. Also, there was no significant decrease in viability in the cells treated with PTX plus IONP-LPrA2. This may be due, in part, to PTX’s anti-microtubule action, which affects the M phase of the cell cycle[25]. Cis, CTX, and Dox act on DNA which affects the S phase[25]. These drugs may work synergistically with IONP-LPrA2, which also appears to act on the S phase. These data indicate that IONP-LPrA2 may act as a chemotherapeutic adjuvant by decreasing viability, thereby decreasing the effective dose in TNBC.

In conclusion, IONP-LPrA2 was found to decrease the level of leptin-induced targets pSTAT3 and cyclin D1. IONP-LPrA2 decreased DNA synthesis during the S phase of the cell cycle and reduced proliferation in both ER+ and TNBC cells. When combined with chemotherapeutics, particularly drugs targeting the S phase, IONP-LPrA2 showed an additive effect on the reduction of live breast cancer cells. These findings indicate that IONP-LPrA2 may be useful in the prevention of tumor cell growth and proliferation in breast cancer. Further, treatment with IONP-LPrA2 may allow for lower chemotherapeutic dosing. These results are potentially beneficial for obese patients with elevated leptin levels, whom have a higher incidence and thus poorer outcome of TNBC. Taken together, the present data provides confirmation of our hypothesis that IONP-LPrA2 treatment may be useful in impairing tumor growth andwhen given in combination with the indicated chemotherapeutics has the potential to increase drug effectiveness. These data indicate that there is a synergistic effect with IONP-LPrA2 and chemotherapeutics which affect the S phase of the cell cycle *in vitro*.

**ACKNOWLEDGEMENTS**

The authors warmly thank Dr. Ming Bo Huang for facilitating the nanoparticle tracking analysis. We also thank Mr. Patrick Abramson and Ms. Aria Armstrong for aesthetic assistance with diagrams and figures.

**COMMENTS**

***Background***

Obesity and high leptin levels are strongly associated with breast cancer relapse, drug resistance, and poorer patient outcomes. Overexpression of leptin and its receptor, Ob-R, induce breast cancer cell growth and proliferation. Triple negative breast cancer (TNBC) is a subtype of breast cancer which comprises approximately 15% of cases and is an aggressive form of the disease with no targeted therapy. TNBC chemotherapeutic treatment often leads to chemoresistance and shows several undesirable side effects. Leptin is proliferative and is a survival factor for breast cancer treated with chemotherapeutics. Therefore, the authors have developed a leptin peptide receptor antagonist coupled to iron oxide nanoparticles (IONP-LPrA2), which successfully inhibits leptin signaling as well as increases chemotherapeutic effectiveness in breast cancer and is particularly promising for TNBC treatment.

***Research frontiers***

IONP-LPrA2 could be a new and effective biological for blocking pro-oncogenic and drug resistance effects of leptin in breast cancer, especially in obese patients suffering from TNBC that are treated with chemotherapeutics.

***Innovations and breakthroughs***

This study describes for the first time the production and characterization of a new biological bound to nanoparticles that can effectively block leptin signaling inducing proliferation and survival in breast cancer cells treated with chemotherapeutics.

***Applications***

In recent years, IONPs have become an important tool for biomedical applications. The use IONPs has been employed in vaccinations, drug delivery, MRI, and molecular imaging. The authors’ data suggests combining IONPs with the leptin antagonist, LPrA2, prevents the growth of breast cancer cells and acts as a chemotherapeutic adjuvant by reducing the effective dose.

***Terminology***

Leptin signaling occurs when the hormone is secreted by the adipose tissue and binds to its receptor, Ob-R. Breast cancer, particularly in obese individuals, is associated with high levels of leptin. Leptin signaling leads to increased breast cancer cell growth, proliferation and drug resistance. The inhibition of leptin signaling with the nanoparticle-linked leptin antagonist, IONP-LPrA2, provides a promising new way to improve breast cancer chemotherapy.

***Peer-review***

This manuscript provides useful information to the medical students, clinicians, and researchers in this field, therefore, is acceptable for publication.

**REFERENCES**

1 **American Cancer Society**. 2015-2016. Available from: URL: http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-key-statistics

2 **Chavez KJ**, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. *Breast Dis* 2010; **32**: 35-48 [PMID: 21778573 DOI: 10.3233/BD-2010-0307]

3 **Boyle P**. Triple-negative breast cancer: epidemiological considerations and recommendations. *Ann Oncol* 2012; **23** Suppl 6: vi7-v12 [PMID: 23012306 DOI: 10.1093/annonc/mds187]

4 **Hudis CA**, Gianni L. Triple-negative breast cancer: an unmet medical need. *Oncologist* 2011; **16** Suppl 1: 1-11 [PMID: 21278435 DOI: 10.1634/theoncologist.2011-S1-01]

5 **Protani M**, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. *Breast Cancer Res Treat* 2010; **123**: 627-635 [PMID: 20571870 DOI: 10.1007/s10549-010-0990-0]

6 **Rock CL**, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. *J Clin Oncol* 2002; **20**: 3302-3316 [PMID: 12149305 DOI: 10.1200/JCO.2002.03.008]

7 **Guo S**, Colbert LS, McGlothen TZ, Gonzalez-Perez RR. Regulation of Angiogenesis in Human Cancer via Vascular Endothelial Growth Factor Receptor -2 (VEGFR-2). In Tumor Angiogenesis, 2011. Available from: URL: http://www.intechweb.org/

8 **Gonzalez RR**, Leavis PC. A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells. *Endocrine* 2003; **21**: 185-195 [PMID: 12897384 DOI: 10.1385/ENDO: 21: 2: 185]

9 **Gonzalez RR**, Leavis PC. Leptin Peptide Antagonists, USSN 7612043, 2009

10 **Guo S**, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. *Biochim Biophys Acta* 2012; **1825**: 207-222 [PMID: 22289780 DOI: 10.1016/j.bbcan.2012.01.002]

11 **Guo S**, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. *Biochim Biophys Acta* 2011; **1815**: 197-213 [PMID: 21193018 DOI: 10.1016/j.bbcan.2010.12.002]

12 **Gao Q**, Horvath TL. Cross-talk between estrogen and leptin signaling in the hypothalamus. *Am J Physiol Endocrinol Metab* 2008; **294**: E817-E826 [PMID: 18334610 DOI: 10.1152/ajpendo.00733.2007]

13 **Bassi M**, Furuya WI, Zoccal DB, Menani JV, Colombari E, Hall JE, da Silva AA, do Carmo JM, Colombari DS. Control of respiratory and cardiovascular functions by leptin. *Life Sci* 2015; **125**: 25-31 [PMID: 25645056 DOI: 10.1016/j.lfs.2015.01.019]

14 **Gonzalez RR**, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, Rueda BR. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). *J Biol Chem* 2006; **281**: 26320-26328 [PMID: 16825198 DOI: 10.1074/jbc.M601991200]

15 **Rene Gonzalez R**, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. *Breast Cancer Res* 2009; **11**: R36 [PMID: 19531256 DOI: 10.1186/bcr2321]

16 **Gillespie C**, Quarshie A, Penichet M, Gonzalez-Perez RR. Potential Role of Leptin Signaling in DMBA-induced Mammary Tumors by Non-Responsive C57BL/6J Mice Fed a High-Fat Diet. *J Carcinogene Mutagene* 2012: **3**: 132 [DOI: 10.4172/2157-2518.1000132]

17 **Crujeiras AB**, Carreira MC, Cabia B, Andrade S, Amil M, Casanueva FF. Leptin resistance in obesity: An epigenetic landscape. *Life Sci* 2015; **140**: 57-63 [PMID: 25998029 DOI: 10.1016/j.lfs.2015.05.003]

18 **James FR**, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer--what is the risk factor? *Eur J Cancer* 2015; **51**: 705-720 [PMID: 25747851 DOI: 10.1016/j.ejca.2015.01.057]

19 **Gonzalez RR**, Leavis PC. Leptin Peptide Antagonists. 2004 Patent US. 7407929, Application No. 10/841, 218; International application No. PCT/US 05/15198

20 **Yang L**, Peng XH, Wang YA, Wang X, Cao Z, Ni C, Karna P, Zhang X, Wood WC, Gao X, Nie S, Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. *Clin Cancer Res* 2009; **15**: 4722-4732 [PMID: 19584158 DOI: 10.1158/1078-0432.CCR-08-3289]

21 **Battle M**, Gillespie C, Quarshie A, Lanier V, Harmon T, Wilson K, Torroella-Kouri M, Gonzalez-Perez RR. Obesity induced a leptin-Notch signaling axis in breast cancer. *Int J Cancer* 2014; **134**: 1605-1616 [PMID: 24114531 DOI: 10.1002/ijc.28496]

22 **Fillmore CM**, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. *Breast Cancer Res* 2008; **10**: R25 [PMID: 18366788 DOI: 10.1186/bcr1982]

23 Cell Signaling Technology. CST Guide: Pathways & Protocols, 2015

24 **Cioce M**, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P, Ciliberto G. Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. *Cell Cycle* 2010; **9**: 2878-2887 [PMID: 20581442]

25 **Aysola K**, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ, Reddy SP, Rao VN. Triple Negative Breast Cancer - An Overview. *Hereditary Genet* 2013; **2013**: [PMID: 25285241 DOI: 10.4172/2161-1041.S2-001]


26 **Scolaro L**, Cassone M, Kolaczynski JW, Otvos L Jr, Surmacz E. Leptin-based therapeutics. *Expert Rev Endocrinol Metab* 2010; **5**: 875-889


27 **Otvos L**, Kovalszky I, Riolfi M, Ferla R, Olah J, Sztodola A, Nama K, Molino A, Piubello Q, Wade JD, Surmacz E. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. *Eur J Cancer* 2011; **47**: 1578-1584 [PMID: 21353530 DOI: 10.1016/j.ejca.2011.01.018]

28 **Yang E**, Qian W, Cao Z, Wang L, Bozeman EN, Ward C, Yang B, Selvaraj P, Lipowska M, Wang YA, Mao H, Yang L. Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. *Theranostics* 2015; **5**: 43-61 [PMID: 25553097 DOI: 10.7150/thno.10350]


29 **Rodler E**, Korde L, Gralow J. Current treatment options in triple negative breast cancer. *Breast Dis* 2010; **32**: 99-122 [PMID: 21778572 DOI: 10.3233/BD-2010-0304]

**P-Reviewer:** Sonoda K, Zhang XQ **S-Editor:** Ji FF **L-Editor: E-Editor:**


**Figure 1 Generation and characterization of iron oxide nanoparticles-LPrA2.** A: Conjugation of iron oxide nanoparticles (IONP)-LPrA2.LPrA2 was conjugated to IONPs *via* 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC), which activates the carboxyl group on the IONP surface allowing it to form a covalent bond with the amino group of LPrA2 (displayed by TEM, transmission electron microscopy, Ocean Nanotech); B: Western blot confirmation of IONP-LPrA2 conjugation.Conjugated IONP-LPrA2 (100 kD) was detected by Western blot with an LPrA2 antibody, purified from antigen injected rabbit bleeds. Unconjugated LPrA2 (3 kD) and the scrambled peptide LPrA2-Sc (3 kD) served as positive and negative controls, respectively; C: NanoSight analysis of unconjugated and conjugated IONPs. The particle size of unconjugated IONP (14 nm) shown in black and the conjugated IONP-LPrA2 (20 nm) shown in red were determined by nanoparticle tracking analysis. The hyperbolic curve shows that the particles are 100% homogeneous.

**


**Figure 2** **Ob-R expression and effect of iron oxide nanoparticles-LPrA2 on leptin-induced pSTAT3 and cyclin D1 levels in human breast cancer cells.** A: Detection of Ob-R expression. The expression of Ob-R was detected by Western blot in MDA-MB-231, HCC1806, and MCF-7 cells; B: Iron oxide nanoparticles (IONP)-LPrA2 inhibition of leptin-induced pSTAT3 and cyclin D1 levels. Lysates were obtained from MDA-MB-231, HCC1806, and MCF-7 cells treated with leptin (1.2 nmol/L) or IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L) for 24-48 h. pSTAT3 and cyclin D1 levels were detected by Western Blot. STAT3 served as a loading control for pSTAT3. GAPDH served as a loading control for cyclin D1; C: Densitometric analysis of pSTAT3 and cyclin D1 levels. Graphs represent quantitative analysis of pSTAT3 and cyclin D1 levels in MDA-MB-231, HCC1806, and MCF-7 cells with Image J software. Relative protein level was significantly increased in leptin treated cell lines compared to basal (untreated) cells, a*P* < 0.05. Relative protein level in cells pretreated with IONP-LPrA2 and then leptin differed significantly from those treated with leptin alone, c*P* < 0.05.

****


**Figure 3 Iron oxide nanoparticles-LPrA2 inhibits leptin-induced cell cycle progression of human breast cancer cell lines.** Iron oxide nanoparticles (IONP)-LPrA2 inhibits S phase progression in breast cancer cells. A: MDA-MB-231; B: HCC1806; C: MCF-7. The cells were seeded in 6 well plates and treated with leptin (1.2 nmol/L), LPrA2 (1.2 nmol/L) plus leptin (1.2 nmol/L), or IONP-LPrA2 at indicated concentrations plus leptin (1.2 nmol/L) for 24-48 h. The percentage of cells in S phase was determined by cell cycle analysis, a measure of propidium iodide (PI) fluorescence. Relative percentage of cells in S phase was significantly increased in leptin treated cell lines compared to basal (untreated) cells, a*P* < 0.05. Relative percentage of cells in S phase pretreated with leptin antagonists and then leptin differed significantly from those treated with leptin alone, c*P* < 0.05.


****

**Figure 4 Iron oxide nanoparticles-LPrA2 inhibits leptin-induced cell proliferation in human breast cancer cells.** MDA-MB-231, HCC1806, and MCF-7 cells were seeded in 96 well plates and treated with leptin (1.2 nmol/L) and iron oxide nanoparticles (IONP)-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L) for 24-48 h. Cell proliferation was determined by MTT assay. Relative percentage of proliferating cells was significantly increased in leptin treated cell lines compared to basal (untreated) cells, a*P* < 0.05. Relative percentage of proliferating cells pretreated with IONP-LPrA2 and then leptin differed significantly from those treated with leptin alone, c*P* < 0.05.



**Figure 5 Iron oxide nanoparticles-LPrA2 decreases MDA-MB-231 tumorsphere formation.** A: Iron oxide nanoparticles (IONP)-LPrA2 attenuation of leptin-induced tumorsphere formation. MDA-MB-231 cells were grown in low attachment plates with mammocult medium for 1-2 wk, under treatment with leptin (1.2 nmol/L) and IONP-LPrA2 (0.0036 pmol/L) plus leptin (1.2 nmol/L). Tumorspheres were counted. Tumorspheres were grouped according to size: Small (< 100 µm), medium (100-200 µm) and large (> 200 µm); B: Effect of leptin and IONP-LPrA2 on number and size of tumorspheres. Graph represents quantitative analysis of small, medium, and large tumorspheres in response to leptin and IONP-LPrA2 treatment. The number of colonies was significantly increased in leptin treated cells compared to basal (untreated) cells, a*P* < 0.05. The number of colonies pretreated with IONP-LPrA2 and then leptin differed significantly from those treated with leptin alone, c*P* < 0.05.

**Figure 6 The effect of chemotherapeutics on survival of breast cancer cell lines.** The effective dose of the chemotherapeutics. A: Cisplatin (Cis); B: Cyclophosphamide (CTX); C: Doxorubicin (Dox); D: Paclitaxel (PTX) were determined in MDA-MB-231, HCC1806, and MCF-7 cells. The cells were seeded in 6 well plates and treated with Cis (0.001-1.1 µmol/L), CTX (0.01-100 µmol/L), Dox (0.01-50 µmol/L), and PTX (0.05-1.0 µmol/L) for 1-6 d. Percent survival was determined by the Annexin V/FITC and PI assay. The relative survival was determined by multiplying the percentage of live cells by the total cell count.

****

**Figure 7 Determination of the effect of iron oxide nanoparticles-LPrA2 on survival of breast cancer cells treated with chemotherapeutics.** MDA-MB-231, HCC1806, and MCF-7 cells were treated with an effective dose of the chemotherapeutics. A: Cisplatin (Cis); B: Cyclophosphamide (CTX); C: Doxorubicin (Dox); D: Paclitaxel (PTX) plus IONP-LPrA2 (0.0036 pmol/L). The cells were seeded in 6 well plates and treated with chemotherapeutics at effective concentrations determined in figure 6 for 1-6 d. The treatment concentrations were MDA-MB-231 (Cis 0.001 µmol/L, CTX 0.5 µmol/L, Dox 0.4 µmol/L, PTX 0.5 µmol/L); HCC1806 (Cis 0.036 µmol/L, CTX 1 µmol/L, Dox 10 µmol/L, PTX 0.5 µmol/L); and MCF-7 (Cis 0.036 µmol/L, CTX 5 µmol/L, Dox 0.01 µmol/L, PTX 1 µmol/L). Percent of survival was determined by the Annexin V/FITC and PI assay. The relative survival was determined by multiplying the percentage of live cells by the total cell count. Perecent viability was significantly decreased in cells treated with chemotherapeutic compared to basal (untreated) cells, a*P* < 0.05. Cells treated with chemotherapeutic and IONP-LPrA2 differed significantly from those treated with chemotherapeutic alone, c*P* < 0.05.